Document:

EXHIBIT 10.2
                                                                    ------------

                       RESEARCH AND DEVELOPMENT AGREEMENT
                                     BETWEEN
             ARTANN LABORATORIES INC, ARMEN SARVAZYAN AND PROUROCARE
                                  MEDICAL INC.

Upon the effective date of this agreement:

1.   Armen Sarvazyan shall be named Chief Scientific  Officer(a consultant - non
     employee) of ProUroCare  Medical Inc. Armen Sarvazyan will be provided with
     the information  and access to the research and  development  process and a
     decision making council, sufficient to be effective in his role.

2.   The Intellectual  Property and know-how  resulting from any new advancement
     of the SGDRE  developed,  for example  the  (position  technology)  will be
     assigned to ProUroCare. ProUroCare must ensure that technology transfer and
     participation  of Artann and Armen  Sarvazyan in continuous  development of
     the SGDRE is covered by the current  agreement  and  understanding  between
     ProUroCare  and  Profile,  and in any way will not present a breach of past
     obligations  of Artann and Armen  Sarvazyan to Profile LLC (formerly  Armed
     LLC).

3.   Artann  Laboratories  shall  be  a  research  and  development  partner  to
     ProUroCare  Medical  Inc. In this  relationship  Artann  shall  support and
     further the development of the Sensor Guided DRE product. Specific material
     engagements will be subject to the separate development  agreements between
     Artann and ProUroCare.

4.   In addition,  Artann shall work on other mutually agreed upon  technologies
     and  products in the field of Urology.  The specific  material  engagements
     will be subject  to  separate  development  agreements  between  Artann and
     ProUroCare.  ProUroCare  shall be assigned  the rights to all  intellectual
     properties  resulting from this work in the area related to the SGDRE.  New
     technology  not related to the SGDRE will be addressed by separate  license
     and royalty agreements.

5.   This  Agreement  shall have an initial  term of 3 years and can be extended
     for a similar term upon mutual consent of all parties to this agreement.

CASH COMPENSATION

An  amount  of  $250,000  shall be paid to  Artann  for the  engagement  in this
research and  development  agreement  and the  assignment  to  ProUroCare of all
patents that  encompasses  new IP developed with respect to the SGDRE.  Payments
shall be made in accordance  with the following  schedule of  performance  based
events:

     o    Effective date (signing) of this agreement                    $ 50,000

     o    Shipment of the SGDRE  Systems in accordance
          with the  Development  Agreement  signed  by
          both   parties.   A  bonus  of  10%  of  the
          milestone  payment  per month  for  delivery
          ahead of  schedule  will be added.  A 10% of
          the  milestone  payment  per month  late fee
          shall be deducted.  The milestone payment is
          due in full if the Development  Agreement is
          terminated by ProUroCare.                                    $ 100,000

<PAGE>

     o    Filing of the patent                                          $ 50,000

     o    Issuance  of  the  patent  (patent  will  be
          assigned to ProUroCare)                                       $ 50,000

WARRANTS

500,000  (five year term)  warrants  shall be issued at the market  price at the
time of issue or $2.00, whichever is lower. The warrants will be vested over the
period of three years according to the following schedule:

     o    100,000 upon execution of this agreement;

     o    200,000 upon  shipment of SGDRE Systems  according to the  Development
          Agreement.  The  200,000  warrant  payment  is  due  in  full  if  the
          Development Agreement is terminated by ProUroCare;

     o    100,000 one year anniversary of the execution date of this agreement.

     o    100,000 two year anniversary of the execution date of this agreement.

The issuance of the last two hundred  warrants is  contingent on the delivery of
clinical units by Minnetronix per the development agreement with ProUroCare.

Note
Warrants will be issued in two names:
90 % in name of Artann Laboratories
10% in name of Vlada International

ARTANN LABORATORIES, INC.               ARMEN SARVAZYAN

By:  /s/Armen Sarvazyan                 By: /s/ Armen Sarvazyan
  ------------------------                -------------------------

Its: Chief Scientist
   -----------------------

PROUROCARE MEDICAL INC.

By: /s/Michael P. Grossman
  ------------------------

Its: President & CEO
   -----------------------

                                       2EXHIBIT 10.3
                                                                    ------------

                              DEVELOPMENT AGREEMENT
                                       FOR
                                SENSOR GUIDED DRE

This document  serves as a Development  Agreement  for  ProUroCare  Medical Inc.
(ProUroCare)  pertaining  to the  development  of the Prostate  Tactile  Imaging
System  (Sensor  Guided  DRE)  with the  positioning  capability.  Work is to be
performed by Artann  Laboratories,  Inc. (Artann) and Armen Sarvazyan in concert
with  Minnetronix  Inc. for ProUroCare in accordance  with the details  outlined
below.

1.   DESIGN FREEZE AND ASSEMBLY OF A PROTOTYPE.

Scope:
------

     o    Stage 1. Finalize the design of all components of the Prostate Tactile
          Imaging  System with the  positioning  capability.  Add to the current
          angular   orientation   system  additional  axial  positioning  means.
          Redesign the  transrectal  probe to accommodate  the components of the
          positioning  system.  Build a prototype probe with optimized  geometry
          and tactile sensor array configuration.  Make necessary changes in the
          software to provide  simultaneous  acquisition  and  processing of the
          position and pressure  pattern data.  Test and validate the components
          and the  entire  assembly  in  laboratory  experiments,  document  the
          testing results.

     o    Duration of Stage 1 is 2 months and the budget is $100,000.

     o    Stage 2. Build 2 (two)  prototypes  of the  Prostate  Tactile  Imaging
          System with the positioning capability. Design algorithms and software
          for the real-time  reconstruction  and imaging the  prostate.  Perform
          evaluation  testing of the prototype.  Possibly,  the prototype  could
          also be tested in  clinical  environment  on a few  patients,  however
          clinical   testing  will  not  constitute  an  obligation  under  this
          contract.

     o    Duration of Stage 2 is 3 months and the budget is $80,000.

Total duration:    5 months
---------------

Total budget:      $180,000
-------------

2.   ASSISTANCE TO MINNETRONIX INC.

Artann Laboratories shall assist Minnetronix Inc. or an alternative appointed by
ProUroCare  in the  development  of the  systems  for  evaluation  in a clinical
environment.  This service  relationship  shall include Artann's  cooperation in
development of a complete Technical Data File by Minnetronix Inc.

Duration:  Artann's  services could be requested after 3 months from the date of
signing of this  agreement.  The no-fee  consulting and at-cost  services option
will be  available  for 6 months  from the start date of the  relationship  with
Minnetronix  and could be extended  per mutual  agreement of both  parties.  The
completion of the service  portion of the agreement is expected to extend beyond
the SGDRE system delivery and will not be used as a milestone for the purpose of
the agreement or the R&D Agreement.

<PAGE>

Cost:  Artann's  staff  including  Armen  Sarvazyan  will  be  available  to the
designated  engineers from  Minnetronix Inc. at no charge for the consulting and
advisory  services  including:  unlimited  telephone  consultations  and  Artann
facilities   visits.   Any   additional   hardware  and  software   development,
experimental work, document  preparation or travel requested by Minnetronix Inc.
will be billed to ProUroCare at reasonable  cost according to hours spend on the
project.  The  reasonableness  of such  requests  will be  mediated by a trustee
designated by both parties, namely Vladimir Drits.

Payment:  The payment  shall be  distributed  in  accordance  with the following
schedule:

     o    50% advance payment upon commencement of each milestone.

     o    50% final payment upon delivery of each milestone.

Notes: Start date shall be July 15, 2004. Payment Terms: Net 15, 3% interest per
month applies after the 15-day period.

ARTANN LABORATORIES, INC.

By:  /s/Armen Sarvazyan
  ------------------------
Its: Chief Scientist
   -----------------------

PROUROCARE MEDICAL INC.

By:  /s/Michael P. Grossman
  -------------------------

Its: President and CEO
   ------------------------

ARMEN SARVAZYAN

By:  /s/Armen Sarvazyan
  ------------------------

                                       2EXHIBIT 10.4
                                                                    ------------

                             LETTER OF UNDERSTANDING

ProUroCare Inc.
One Carlson Parkway North
Suite 124
Plymouth, MN 55447

March 23, 2004

Profile, LLC
c/o Mr. Stan Graves
2700 Corporate Drive, Suite 120
Birmingham, Alabama  35242

with a copy to:

Peter C. Quittmeyer, Esq.
Sutherland, Asbill & Brennan, LLP
999 Peachtree Street, Suite 1900
Atlanta, GA  30309

Gentlemen:

     This   letter   sets  forth  the   agreement   between   ProUroCare,   Inc.
("ProUroCare"), and Profile, LLC ("Profile").

     Profile and  ProUroCare  have entered  into the  following  agreements  and
relationships:

     (a)  Stock Purchase Agreement,  dated January 14, 2002, between Profile and
          ProUroCare,  as amended on March 22,  2002 with a First  Amendment  to
          Stock Purchase Agreement (as amended the "Purchase Agreement").

     (b)  License  Agreement  between Profile and ProUroCare,  dated January 14,
          2002,  as amended on March 22, 2002 with a First  Amendment to License
          Agreement (as amended, the "License").

     (c)  Amended and Restated  Shareholder Control and Share Transfer Agreement
          between ProUroCare, Profile, Clinical Network, Inc., Clinical Network,
          LLC,  and CS Medical  Technologies,  LLC dated  January  14, 2002 (the
          "Shareholder Agreement").

     (d)  Profile owns 1,333,333 shares of common stock of ProUroCare.

     (e)  Profile has given notice to ProUroCare that it is in default under the
          License and ProUroCare has denied that it is in default.

<PAGE>

     (f)  ProUroCare held a special  Shareholders'  Meeting on March 5, 2004, at
          which the shareholders of ProUroCare approved the merger of ProUroCare
          with GIC Acquisition  Corp.  ("GIC"),  a subsidiary of Global Internet
          Communications, Inc. ("Global") whereby the shareholders of ProUroCare
          will exchange  their shares of  ProUroCare  common stock for shares of
          Global  common  stock (the  "Merger")  all as described in the Private
          Placement Memorandum (hereinafter defined).

     (g)  On March 3, 2004,  Profile exercised the dissenters'  rights on behalf
          of  beneficial  owners  owning  308,465  shares  of  common  stock  of
          ProUroCare.

     (h)  Global is engaged  in a private  placement  of a minimum of  1,500,000
          shares of Global  common  stock and a maximum of  2,500,000  shares of
          Global common stock at $2.00 per share pursuant to a private placement
          memorandum  dated February 11, 2004, as supplemented by Supplement No.
          1, dated March 23, 2004 (the "Private Placement") (as so supplemented,
          the "Private Placement Memorandum").

     (i)  Maurice R. Taylor,  II,  ("Taylor")  owns  beneficially  approximately
          1,041,315  shares  of common  stock of  ProUroCare.  Of these  shares,
          847,982  shares of  ProUroCare  common  stock  are  owned by  Clinical
          Network,  LLC, and 85,000 shares of ProUroCare  common stock are owned
          by Clinical  Network,  Inc.  Taylor's  ownership also includes 108,333
          shares  that are subject to options.  Based on Taylor's  ownership  in
          Clinical  Network,  LLC  and  Clinical  Network,  Inc.,  approximately
          589,815 shares of common stock of ProUroCare are owned beneficially by
          Taylor and his family.  The  remaining  342,302  shares of  ProUroCare
          common stock owned by Clinical Network, LLC and Clinical Network, Inc.
          are owned  beneficially  by persons or entities that are not otherwise
          affiliated with Taylor.

     Based upon the preceding, the parties hereto agree as follows:

     1. All  continuing  obligations of ProUroCare to Profile under the Purchase
Agreement  including,  without  limitation,  Sections  4.2,  4.3 and 4.4,  shall
terminate  upon the  Effective  Date and shall be of no further  force or effect
after the Effective Date (as hereinafter defined).

     2. The  Shareholder  Agreement shall terminate as of the Effective Date and
be of no further force or effect after the Effective Date,  contingent only upon
Clinical Network, LLC, Clinical Network,  Inc. and CS Medical Technologies,  LLC
agreeing in writing to terminate the Shareholder Agreement.

     3. As of the Effective  Date,  Profile  withdraws its default letters under
the License and waives any  existing  defaults  under the  License.  This waiver
shall in no way limit the ability of Profile to enforce its rights and  remedies
for defaults by ProUroCare  occurring  after to the Effective Date. For purposes
of Section  7.4(e) of the License,  in the event of a termination of the License
after the  Effective  Date,  Profile  shall be obligated to return the number of
Global shares issued to ProUroCare in the proposed merger in respect of one-half
of the  original  1,076,923  shares of  ProUroCare  stock  acquired  by  Profile
pursuant to the Stock  Purchase  Agreement  (subject to adjustment for any stock
splits or dividends or exchange ratios under the Merger).

     4.  ProUroCare  agrees  that of the funds  raised by Global in the  Private
Placement not less than $1,200,000 will be used by ProUroCare in connection with
the research, development and commercialization of the "Devices" as that term is
defined in the  License;  provided,  however,  said amount may be reduced by any
amounts paid to Profile  pursuant to Section 6 hereof and will be increased  (to
the amount of such reduction from  $1,200,000) to the extent  ProUroCare  raises
more than  $3,000,000  in the  Private  Placement  as  provided  in the  Private
Placement Memorandum or in any subsequent financing.

                                        2
<PAGE>

     5. As of the  Effective  Date,  Profile  agrees to transfer  to  ProUroCare
300,000 shares of ProUroCare common stock.

     6. As  consideration  for  the  agreements  of  Profile  contained  in this
Agreement,  ProUroCare  shall pay Profile  $750,000;  $100,000 of which shall be
payable as of the Effective Date, $325,000 of which shall be payable ninety (90)
days months after the Effective  Date,  and the final $325,000 of which shall be
payable within six (6) months after the Effective  Date.  Profile will receive a
Promissory  Note  ("Note")  for the  remaining  $650,000  outstanding  as of the
Effective  Date,  which will  accrue  interest  at the rate of six and  one-half
percent (6 1/2 %) per year and, in the event of default in payment,  will accrue
eight and one-half percent (8 1/2 %) after the payment  default.  ProUroCare may
prepay  the  Note at any  time.  The  Note  will be  secured  by the  assets  of
ProUroCare,  including its intellectual  property, in accordance with a security
agreement  mutually  acceptable  to  both  parties,  which  shall  be  executed,
delivered and perfected  immediately  upon (and as a condition to) the Effective
Date.  ProUroCare's  counsel  will  prepare the Note,  a security  agreement,  a
collateral  patent  assignment,  an  assignment  of license and a UCC  Financing
Statement  to  perfect  Profile's  security  interest  in  ProUroCare's   assets
(including its intellectual property), subject to approval by Profile's counsel,
not to be  unreasonably  withheld  or delayed.  ProUroCare  shall cause said UCC
Financing  Statements  and  Collateral  Patent  Assignments to be properly filed
immediately  upon  (and as a  condition  to) the  Effective  Date.  Profile  and
ProUroCare shall each pay its own attorneys' fees.

     7. The transfer of 300,000  shares of ProUroCare  common  stock,  as of the
Effective Date, pursuant to this Agreement shall have the effect of settling any
dissenters'  rights claims Profile or its beneficial owners have with respect to
the  Merger  or on  account  of  Profile's  exercise  of  dissenters'  rights as
described in  paragraph  (g) above.  The  remaining  8,465 shares of  ProUroCare
common stock for which  dissenters'  rights were exercised  shall be returned to
Profile and shall participate in the Merger.

     8. As of the  Effective  Date,  Taylor  agrees  that he will  dispose of no
shares of  ProUroCare  common stock that he or his family  beneficially  owns so
long as any  amounts  are owing  under the Note to  Profile,  including  without
limitation any shares of ProUroCare common stock acquired in connection with the
exercise by Taylor or his family of any  options or warrants to purchase  shares
of  ProUroCare  common  stock;  provided,  however,  that in the event  Clinical
Network, LLC or Clinical Network,  Inc. distributes its shares to its beneficial
owners,  then any person or entity not  affiliated  with  Taylor may sell shares
that were previously owned by Clinical Network,  LLC and Clinical Network,  Inc.
and not be subject to these limitations;  and, provided further, that Taylor may
sell up to 300,000 shares multiplied by a fraction,  the denominator of which is
$750,000 and the numerator of which is the sum of the amount of principal  under
the Note that has been paid by ProUroCare to Profile plus the original  $100,000
paid on the  Effective  Date.  For example,  Taylor may sell 40,000 shares after
ProUroCare pays $100,000 to Profile,  and Taylor may sell an additional  130,000
shares after  ProUroCare  makes its $325,000  payment to Profile.  The foregoing
share totals are also subject to adjustment for any stock splits or dividends or
exchange  ratios under the Merger.  References  in this Section 8 to  ProUroCare
shares  shall  include any Global  common  stock  received in exchange  for such
ProUroCare shares.

     9. (a) Global  shall  prepare and file with the SEC,  within 120 days after
the final closing of the Private  Placement,  a  registration  statement on Form
SB-2 with  respect to resale of shares of Global  common  stock,  including  all
shares of Global common stock held by Profile or its  transferees,  from time to
time   through  the   over-the-counter   market  or  in   privately   negotiated
transactions,  and use its  commercially  reasonable  best  efforts  (subject to
receipt of necessary  information from Profile or its transferees) to cause such
registration to be effective as soon as possible thereafter.

                                        3
<PAGE>

     (b) Global shall prepare and file such  amendments  and  supplements to the
registration  statement as may be necessary to keep such registration  statement
effective for one year from its effective  date or such shorter  period when all
of Global  common stock owned by Profile and its  transferees  have been sold or
may be sold pursuant to Rule 144(k).

     (c) Except to the  extent an  exemption  from  registration  is  available,
Global  agrees to  register  or  qualify  the  resale of such  shares  under all
applicable state securities or blue sky laws of such jurisdictions in the United
States as Profile or any transferee shall reasonably  request,  and to keep each
such  registration or  qualification  effective  during the period when such SEC
registration is required to be kept effective.

     (d) Upon  request,  Global will notify the  shareholders  whose  shares are
being registered when the registration  statement is filed with the SEC and each
state, and Global will notify all shareholders participating in the offering (A)
when the registration  statement is effective (B) when any stop order is issued,
and (C) after such effectiveness, of the happening of any event as the result of
which  the  registration   statement  or  the  prospectus  contains  a  material
misstatement  or  omission,  and in the case of (B) or (C),  Global will use its
best efforts,  as soon as  practicable,  to cause the stop order to be lifted or
the registration statement and prospectus to be amended to correct the problem.

     (e) Global will pay all the costs and expenses of such registrations, other
than  the  legal  fees of any  shareholders'  separate  legal  counsel,  and any
commissions  or fees  relating  to the sale of such  shares,  and  will  defend,
indemnify  and hold the selling  shareholder  harmless for any  liabilities  and
actions in respect  thereof which arise out of (i) any untrue or alleged  untrue
statement  of a  material  fact  contained  in such  registration  statement  or
prospectus  (other than information  furnished by the shareholders for inclusion
therein), (ii) any omission or alleged omission to state therein a material fact
required to be stated  therein or necessary to make the statements  therein,  in
light of the circumstances under which they were made, not misleading,  or (iii)
any  violation  of  any  law,  rule  or  regulation  in  connection   with  such
registration, registration statement or prospectus.

     (f)  During the period  commencing  on the date  hereof and ending one year
following the effective date of the  registration  statement in which the Global
shares of Profile are  registered as described in Section 9(a) above,  if Global
effects any underwritten offering of common stock, and if such offering includes
any shares of Global common stock owned by any Global  shareholder,  then Global
will allow Profile and its  transferees to participate in the offering by giving
Profile at least ten (10) days'  prior  notice.  In the event that the  managing
underwriter  notifies  Global  in  writing  that  the  inclusion  of the  shares
requested  to be so  included  by  Profile  and any  other  Global  shareholders
permitted to  participate  would  materially  interfere  with the  underwriters'
ability to  effectuate  the  registration  and complete the  offering,  then the
number of shares of Global  common  stock of Profile and its  transferees  to be
included in the offering may be cut-back pro rata (based on the number of shares
of Global common stock  requested by Profile and its  transferees to be included
in the offering in relation to the total number of shares of Global common stock
requested by all Global  shareholders to be included in the offering);  provided
that,  in no event,  shall the cut-back for Profile and its  transferees  be any
less favorable than the cut-back for any other Global shareholder.

     (g) Global will take such other  actions at its expense as are customary or
reasonably  requested  by  the  participating   shareholder  to  facilitate  the
registration and sale of shares contemplated by this Section 9.

     10. As of the  Effective  Date,  ProUroCare  and  Profile  will  each,  for
themselves and for their agents, administrators, employees, officers, directors,
shareholders, subsidiaries, affiliates, successors and

                                        4
<PAGE>

assigns,  release and forever  discharge  the other and its past,  present,  and
future officers, directors,  attorneys,  insurers, principals, agents, servants,
representatives,  employees, shareholders,  subsidiaries,  affiliates, partners,
predecessors,  successors  and assigns of and from all past,  present and future
claims, demands, obligations, actions and causes of action, at law or in equity,
whether under statute,  common law, or otherwise,  of whatsoever kind or nature,
from the beginning of time to the Effective Date,  except for obligations of the
parties  contained in this Agreement.  The release of ProUroCare shall expressly
apply to Stanley  Graves and Dr.  Teo F. Dagi and the  release of Profile  shall
expressly  apply to Maurice R. Taylor,  II, David F. Koenig and Alex  Nazarenko.
Notwithstanding any of the foregoing to the contrary,  the release of ProUroCare
shall not apply to Todd  Leonard.  This mutual  release  does not go into effect
with respect to existing claims of the parties against each other, if any, until
the Effective Date. Notwithstanding any of the foregoing to the contrary, except
as expressly  set forth in Section 3 hereof,  the  foregoing  release  shall not
apply to the rights and obligations of the parties under the License.

     11.   Profile  is  entering  into  this  Agreement  in  reliance  upon  the
information disclosed in the Private Placement Memorandum.  Profile has received
a copy of the  Private  Placement  Memorandum.  In the  event  that the  Private
Placement  Memorandum is again supplemented in any material respect prior to the
Effective  Date,  ProUroCare  will cause Profile to receive such supplement in a
timely fashion and, if the changes  disclosed in such supplement have a material
and adverse effect on Profile's  position,  Profile shall have the right, at its
option,  to declare this letter of understanding to be of no force or effect and
void ab initio.

     12. This  Agreement  has been duly  authorized,  executed and  delivered by
ProUroCare  and as of the  Effective  Date will be binding upon and  enforceable
against ProUroCare and, to the extent applicable,  Global in accordance with its
terms.  The  Effective  Date will not occur unless Global agrees (a) to meet its
obligations  under  the  Agreement,   (b)  to  cause  ProUroCare  to  meets  its
obligations  under  this  Agreement,  (c)  to  provide  any  necessary  support,
including  financial support,  for ProUroCare to meet its obligations to Profile
under the  Agreement  and (d) to provide  sufficient  resources to ProUroCare in
such a manner that  ProUroCare  complies with Section  302A.551 of the Minnesota
Business  Corporation  Act with respect to the  redemption of 300,000  shares of
common  stock  pursuant to Section 5 hereof and payment of the amounts set forth
in Section 6 hereof.

     13. The consummation of the transactions  contemplated by this Agreement is
contingent  upon (i) Global  raising  not less than  $3,000,000  in the  Private
Placement, (ii) the Merger being consummated, and (iii) the execution,  delivery
and, as applicable,  perfection of the  instruments  referenced in Section 6 and
payment of the first  installment  of $100,000 as  contemplated  therein.  These
events shall occur no later than April 30, 2004 (the  "Effective  Date") and the
transactions  contemplated  herein shall be effective as of the Effective  Date.
The parties  agree in the event the  conditions  (i) and (ii)  contained in this
Section  are not met by  April  30,  2004,  then  all  the  representations  and
agreements  contained  herein shall be of no further force or effect and nothing
herein  contained  will be  further  binding  on the  parties,  and this  entire
Agreement shall be void ab initio.

     14. The agreements  contained herein are meant to be binding  agreements of
and enforceable against the parties hereto, their successor and assigns.

     15.  Reference to shares of ProUroCare  contained herein shall be to shares
of Global exchanged for ProUroCare  shares as of the Effective Date,  subject to
adjustment  pursuant  to Section 8. All rights of Profile  under this  Agreement
shall  inure to the  benefit  of  Profile's  direct  and  indirect  transferees.
References to Global shall, as the context may require, include any successor or
assign of Global or  ProUroCare  or their  respective  business,  and any parent
corporation or affiliate  whose shares may be exchanged for ProUroCare or Global
shares.

                                        5
<PAGE>

     16. This Agreement may be executed in any number of  counterparts,  each of
which when so executed  and  delivered  will be deemed an  original,  and all of
which together shall constitute one and the same agreement.

     If the foregoing  sets forth your  understanding,  please so acknowledge by
signing a copy of this letter and returning it to the undersigned.

PROUROCARE INC.

By:  /s/ Michael Grossman
  ----------------------------------------------
  Its: President and Chief Executive Officer

Agreed and accepted this 23rd day of March, 2004

PROFILE, L.L.C.

By:  /s/ Stan Graves
  ----------------------------------------------
  Its:  Manager

Agreed and accepted this 23rd day of March, 2004

Agreed and  accepted  this 23rd day of March,  2004  Solely  for the  purpose of
agreeing to Sections 8 hereof:

     /s/ Maurice R. Taylor, II
------------------------------------------------
         Maurice R. Taylor, II

                                        6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]